AIxCrypto and BitMart Launch Co‑Branded Virtual Prepaid Card for Web3 Payments
- AIxCrypto partners with BitMart to launch a co‑branded virtual prepaid card bringing Web3 to everyday digital payments for its community. • AIxCrypto keeps a non‑regulated role: community reach, brand participation and marketing; it doesn't handle issuance or payment settlement. • AIxCrypto highlights BesTrade DeAI Agent and a roadmap integrating AI and blockchain, framing the card as real‑world payments utility.
Co‑branded Virtual Prepaid Card Links Web3 to Everyday Commerce
AIxCrypto announces a strategic partnership with BitMart to launch a co‑branded virtual prepaid card aimed at bringing Web3 capabilities into routine digital payments. The card is designed for everyday online spending and integration with major digital wallet ecosystems, and is available to eligible users subject to applicable terms and regional availability. AIxCrypto positions the product as a practical utility to expand crypto and blockchain use beyond trading and into everyday commerce for its global community.
The agreement deliberately separates roles between the two firms to create a compliant operating model. BitMart acts as the exclusive operator of the card program and assumes responsibility for card issuance, user onboarding, compliance, customer support and all payment infrastructure, including adherence to regulatory, licensing and network requirements. AIxCrypto contributes community reach, brand participation and marketing channels, keeping its role focused on ecosystem engagement rather than regulated financial operations.
The collaboration underscores AIxCrypto’s strategic emphasis on scalability and regulatory clarity as it seeks to bridge Web2 and Web3 experiences. The card supports major digital wallet networks and merchants that accept prepaid cards, while specifics such as rollout timing, eligibility criteria, transaction limits, fees and supported currencies are disclosed by BitMart in line with regional laws, licensing timelines and payment network rules. The announcement contains customary forward‑looking language noting that expected actions and results are subject to risks and uncertainties.
Operational and Compliance Boundaries
BitMart bears sole responsibility for the regulated elements of the program, including obtaining any required licenses and meeting consumer protection standards in each jurisdiction where the card becomes available. AIxCrypto’s role is explicitly non‑regulated, focusing on marketing, community channels and product participation to drive adoption without handling issuance or payment settlement.
Product Roadmap and Ecosystem Focus
AIxCrypto highlights its BesTrade DeAI Agent and other AIxC ecosystem products as part of a broader roadmap to integrate artificial intelligence and blockchain. The company frames the card partnership as a step toward real‑world utility for digital asset users, aligning payments functionality with its longer‑term goal of connecting AI services and blockchain infrastructure.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…